Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours
December 3, 2024
December 3, 2024
November 27, 2024
November 19, 2024
November 18, 2024
November 14, 2024
November 8, 2024
October 28, 2024
October 9, 2024
October 8, 2024
April 24, 2025
EpiCypher®, a leader in epigenomics innovation, announces the launch of CUTANA® meCUT&RUN and Multiomic CUT&RUN, two novel DNA methylation seq...
April 8, 2025
Enlarged Leadership Team with CSO, Prof. Dr. Anton Wellstein, and CBO, Dr. Matthias Evers Indivumed is proud to announce major milestones achieved, ce...
April 3, 2025
Innovative Knowledge Discovery Platform to Accelerate Research into Promising Therapeutic Targets for Parkinson’s Disease ONTOFORCE, a leader in seman...
Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225